Severe Generalized Pustular Psoriasis Successfully Treated with Ixekizumab: A Case Report

Generalized pustular psoriasis (GPP) is a severe and potentially life-threatening type of psoriasis. We present the case of a patient with severe GPP, at first unsuccessfully treated with cyclosporine. We chose to treat the patient with ixekizumab, an anti-IL-17 antibody known for its rapid action in psoriasis vulgaris, that has also been reported as effective in GPP. The patient improved rapidly, with resolution of the active lesions after the first administration. The treatment has been continued for 2 years, with no adverse events and sustained disease control. Ixekizumab could be considered a safe and effective option in patients with GPP.

Automated summary

Generalized pustular psoriasis (GPP) is a severe and potentially life-threatening disease. Treatment with ixekizumab can rapidly improve the condition of GPP patients, and long-term treatment for 2 years has shown no adverse events.